CoChat

Metabolic Profiling of the Response to an Oral Glucose Tolerance Test Detects Subtle Metabolic Changes

Open access
Wopereis, Suzan, Rubingh, Carina M., van Erk, Marjan J., Verheij, Elwin R., van Vliet, Trinette, Cnubben, Nicole H. P., Smilde, Age K., van der Greef, Jan, van Ommen, Ben, Hendriks, Henk F. J. · 2009 · PLoS ONE

The DOI matches its Crossref record; 55 of the 56 references it cites were found in a registry or an index.

Abstract

BACKGROUND: The prevalence of overweight is increasing globally and has become a serious health problem. Low-grade chronic inflammation in overweight subjects is thought to play an important role in disease development. Novel tools to understand these processes are needed. Metabolic profiling is one such tool that can provide novel insights into the impact of treatments on metabolism. METHODOLOGY: To study the metabolic changes induced by a mild anti-inflammatory drug intervention, plasma metabolic profiling was applied in overweight human volunteers with elevated levels of the inflammatory plasma marker C-reactive protein. Liquid and gas chromatography mass spectrometric methods were used to detect high and low abundant plasma metabolites both in fasted conditions and during an oral glucose tolerance test. This is based on the concept that the resilience of the system can be assessed after perturbing a homeostatic situation. CONCLUSIONS: Metabolic changes were subtle and were only detected using metabolic profiling in combination with an oral glucose tolerance test. The repeated measurements during the oral glucose tolerance test increased statistical power, but the metabolic perturbation also revealed metabolites that respond differentially to the oral glucose tolerance test. Specifically, multiple metabolic intermediates of the glutathione synthesis pathway showed time-dependent suppression in response to the glucose challenge test. The fact that this is an insulin sensitive pathway suggests that inflammatory modulation may alter insulin signaling in overweight men.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0004525

Cites

55 of 55 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Overview of study design, time points at which metabolome was measured and multivariate data analyses. To determine metabolites that were modulated by the diclofenac treatment the following multivariate data comparisons were performed to identify metabolites that were modulated by the diclofenac treatment: a) PLS-DA on metabolic profiling data from day 9 subtracted by metabolic profiling data from day 0, on fasted plasma samples; b) n-PLS-DA on metabolic profiling data from day 0, 2, 4, 7 and 9, on fasted plasma samples; c) n-PLS-DA on metabolic profiling data from day 9 subtracted by metabolic profiling data from day 0, using the fasted plasma samples and the samples after glucose administration, thus metabolic profiling data on 0, 15, 30, 45, 60, 90, 120 and 180 minutes after glucose administration. The multivariate data comparisons from a-c were performed per metabolite platform, thus multivariate models were created for GC-MS global, LC-MS polar, LC-MS lipids and LC-MS free fatty acids data.
Figure 1 Overview of study design, time points at which metabolome was measured and multivariate data analyses. To determine metabolites that were modulated by the diclofenac treatment the following multivariate data comparisons were performed to identify metabolites that were modulated by the diclofenac treatment: a) PLS-DA on metabolic profiling data from day 9 subtracted by metabolic profiling data from day 0, on fasted plasma samples; b) n-PLS-DA on metabolic profiling data from day 0, 2, 4, 7 and 9, on fasted plasma samples; c) n-PLS-DA on metabolic profiling data from day 9 subtracted by metabolic profiling data from day 0, using the fasted plasma samples and the samples after glucose administration, thus metabolic profiling data on 0, 15, 30, 45, 60, 90, 120 and 180 minutes after glucose administration. The multivariate data comparisons from a-c were performed per metabolite platform, thus multivariate models were created for GC-MS global, LC-MS polar, LC-MS lipids and LC-MS free fatty acids data.CC BY · PubMed Central
Figure 2 OGTT time course mean metabolite response with standard error on day 9 corrected for concentrations on day 0 for subjects on placebo and diclofenac treatment. A) for the metabolite isoleucine that contributes to treatment differences over the whole time course and B) for the metabolite glycine that contributes to treatment differences only in the second part of the time course. Legend to Figure 2: Dashed line: Diclofenac treated subjects; Solid line: Placebo treated subjects.
Figure 2 OGTT time course mean metabolite response with standard error on day 9 corrected for concentrations on day 0 for subjects on placebo and diclofenac treatment. A) for the metabolite isoleucine that contributes to treatment differences over the whole time course and B) for the metabolite glycine that contributes to treatment differences only in the second part of the time course. Legend to Figure 2: Dashed line: Diclofenac treated subjects; Solid line: Placebo treated subjects.CC BY · PubMed Central
Figure 3 Day 0 insulin response in OGTT time course. Day 0 insulin mean response with standard error is shown in OGTT time course for all subjects. Insulin concentrations show a maximum at ∼65 minutes after glucose intake.
Figure 3 Day 0 insulin response in OGTT time course. Day 0 insulin mean response with standard error is shown in OGTT time course for all subjects. Insulin concentrations show a maximum at ∼65 minutes after glucose intake.CC BY · PubMed Central
Figure 4 Glutathione synthesis pathway and its connection to glucose and insulin. High levels of glucose inhibit and high levels of insulin activate glutathione synthesis via the enzyme γ-glutamylcysteine synthetase. Legend to Figure 4: Connection arrows with color red represent inhibition and color green represent activation. Purple hexagons represent metabolites; purple hexagons with white star represent metabolites measured with one of the metabolic profiling platforms; orange symbols represent enzymes. Red arrows upwards indicate that higher plasma concentration levels were found in the diclofenac treated group in response to oral glucose tolerance test. Abbreviations: AA, amino acid; Cys-Gly, cysteinylglycine. These figures were created by using MapEditor version 2.1.0 (GeneGo Inc, St Joseph, MI).
Figure 4 Glutathione synthesis pathway and its connection to glucose and insulin. High levels of glucose inhibit and high levels of insulin activate glutathione synthesis via the enzyme γ-glutamylcysteine synthetase. Legend to Figure 4: Connection arrows with color red represent inhibition and color green represent activation. Purple hexagons represent metabolites; purple hexagons with white star represent metabolites measured with one of the metabolic profiling platforms; orange symbols represent enzymes. Red arrows upwards indicate that higher plasma concentration levels were found in the diclofenac treated group in response to oral glucose tolerance test. Abbreviations: AA, amino acid; Cys-Gly, cysteinylglycine. These figures were created by using MapEditor version 2.1.0 (GeneGo Inc, St Joseph, MI).CC BY · PubMed Central
Figure 5 Dynamic response of glutathione synthesis pathway intermediates in OGTT time course. A) glutathione mean response with standard error on day 9 corrected for concentrations on day 0 for subjects on placebo and diclofenac treatment. Glutathione showed a treatment difference only in the second part of the time course. B) Cysteinylglycine mean response with standard error on day 9 corrected for concentrations on day 0 for subjects on placebo and diclofenac treatment. Cysteinylglycine showed a treatment difference only in the second part of the time course. Legend to Figure 5: Dashed line: Diclofenac treated subjects; Solid line: Placebo treated subjects.
Figure 5 Dynamic response of glutathione synthesis pathway intermediates in OGTT time course. A) glutathione mean response with standard error on day 9 corrected for concentrations on day 0 for subjects on placebo and diclofenac treatment. Glutathione showed a treatment difference only in the second part of the time course. B) Cysteinylglycine mean response with standard error on day 9 corrected for concentrations on day 0 for subjects on placebo and diclofenac treatment. Cysteinylglycine showed a treatment difference only in the second part of the time course. Legend to Figure 5: Dashed line: Diclofenac treated subjects; Solid line: Placebo treated subjects.CC BY · PubMed Central
Figure 6 Day 0 glutathione response in OGTT time course. Day 0 glutathione mean response with standard error is shown in OGTT time course for all subjects. Glutathione showed declined concentrations in the first part of the time course with a minimum concentration at 60 minutes after glucose intake. In the second part of the time course concentrations increase again.
Figure 6 Day 0 glutathione response in OGTT time course. Day 0 glutathione mean response with standard error is shown in OGTT time course for all subjects. Glutathione showed declined concentrations in the first part of the time course with a minimum concentration at 60 minutes after glucose intake. In the second part of the time course concentrations increase again.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 55 references

Cited by

See all 123

Metadata

Authors
Wopereis, S., Rubingh, C. M., van Erk, M. J., Verheij, E. R., van Vliet, T., Cnubben, N. H. P., Smilde, A. K., van der Greef, J., van Ommen, B., & Hendriks, H. F. J.
Affiliations
  • Netherlands Organisation for Applied Scientific Research (NL)
  • University of Amsterdam (NL)
Corresponding author
Wopereis, Suzan
Venue
PLoS ONE
Published
2009-02-26
Volume
4
Issue
2
Pages
e4525
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2074399756
Cited by
123
References
56
Citations by year
2025: 1 · 2024: 5 · 2023: 3 · 2022: 12 · 2021: 6 · 2020: 7 · 2019: 1 · 2017: 4 · 2016: 7 · 2015: 10 · 2014: 12 · 2013: 14 · 2012: 15
FWCI
5.50
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Leiden Repository (Leiden University) (submittedVersion)
  • TNO Repository (submittedVersion)
  • Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
  • UvA-DARE (University of Amsterdam) (submittedVersion, other-oa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Repository hosted by TU Delft Library (TU Delft) (submittedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolomics and Mass Spectrometry Studies
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diet, Metabolism, and Disease
Keywords
metabolite profiling, oral glucose tolerance test, overweight, low-grade inflammation, C-reactive protein, plasma metabolites, insulin signaling, metabolic perturbation
MeSH terms
Blood Glucose, C-Reactive Protein, Glucose Tolerance Test, Glutathione, Humans, Inflammation, Insulin, Male, Mass Spectrometry, Overweight, Metabolic Networks and Pathways, Metabolome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Metabolic Profiling of the Response to an Oral Glucose Tolerance Test Detects Subtle Metabolic Changes. https://app.cochat.ai/papers/10.1371/journal.pone.0004525
The paper
Wopereis, S., Rubingh, C. M., van Erk, M. J., Verheij, E. R., van Vliet, T., Cnubben, N. H. P., Smilde, A. K., van der Greef, J., van Ommen, B., & Hendriks, H. F. J. (2009). Metabolic Profiling of the Response to an Oral Glucose Tolerance Test Detects Subtle Metabolic Changes. PLoS ONE. https://doi.org/10.1371/journal.pone.0004525

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.